XGN רווחיות מכירות גולמית exagen.com

Exagen Inc. (XGN) generates revenue through the sale of AVISE genomic tests for the early diagnosis of lupus. The gross margin growth rate illustrates the effectiveness of this strategy, where the 58.70 mark indicates the current profitability level. Optimization is achieved through the outsourcing of logistics and IT services. Meanwhile, the business's financial stability remains steady, fully covering all operating expenses and capital expenditures.
פילוחי מדדים פיננסיים ומדדי שוק עבור Exagen Diagnostics (XGN)

Gross margin determines the portion of revenue minus direct production costs, serving as a fundamental indicator of cost management efficiency and the issuer's pricing power. Amid intense competition with laboratory networks, the gross margin history of Exagen Inc. (XGN) reflects the company's ability to maintain the premium pricing of diagnostic tests despite the risk of declining insurance reimbursements, which is critical for assessing portfolio resilience.